Heterotopic Ossification Clinical Trial
— POHER IIOfficial title:
Early Ultrasound Screening of Heterotopic Ossification After Severe Neurological Trauma in a Post-intensive Care Rehabilitation Unit
Prospective, bi-centric diagnostic, performance study on a new diagnostic procedure with ultrasounds against a reference diagnostic procedure. The primary objective is to study the performance of ultrasound coupled with clinical examination at 1 week of admission for early screening of heterotopic ossification (HO) in patients admitted to a post intensive care rehabilitation unit (PICRU) after a severe neurologic trauma. The CT scan at 5 weeks of admission is considered as the gold standard. CT scan reader will be blinded to clinical data.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | January 2024 |
Est. primary completion date | January 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients ? 18 years; - Admitted to a neurological post intensive care rehabilitation unit for the first time; - Hospitalized in ICU before being admitted to PICRU for a for traumatic brain injury (initial Glasgow coma scale < 14 and brain radiological abnormalities at the time of admission to ICU and / or a traumatic spinal cord injury (para- or tetraplegia with at least half of key muscles of the 2019 ISNCSCI classification with a strength of less than 3 below the neurological level of the injury at the time of admission to PICRU); - Patient's written consent obtained (or from an authorized relative); - Affiliation to a social security scheme. Exclusion Criteria: - History of moderate or severe traumatic brain injury; - History of spinal cord injury (para- or tetraplegia); - History of stroke or disabling neurological disease; - History of hospitalization in neurological or neurosurgical or traumatological ICU for another reason; - Breast-feeding or pregnancy; - Under court protection. |
Country | Name | City | State |
---|---|---|---|
France | Department of Physical Medicine and Rehabilitation, Raymond Poincaré Hospital, AP-HP | Garche |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris | Fondation Paul Bennetot |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area under the ROC (receiver operating characteristic) curve at 1 week | Area under the ROC curve of ultrasound examination at 1 week compared CT scan at 5 weeks for making the diagnosis of HO. | at 1 week | |
Secondary | Sensitivity | Sensitivity of ultrasound examination at 1 week for making the diagnosis of HO, the CT scan at 5 weeks of admission being considered as the gold standard. | at 1 week | |
Secondary | Specificity | Specificity of ultrasound examination at 1 week for making the diagnosis of HO, the CT scan at 5 weeks of admission being considered as the gold standard. | at 1 week | |
Secondary | Positive predictive value and negative predictive value | Positive predictive value and negative predictive value of ultrasound examination at 1 week for making the diagnosis of HO, the CT scan at 5 weeks of admission being considered as the gold standard. | at 1 week | |
Secondary | Likelihood-ratio of ultrasound | Likelihood-ratio of ultrasound examination at 1 week for making the diagnosis of HO, the CT scan at 5 weeks of admission being considered as the gold standard. | at 1 week | |
Secondary | Area under the ROC curve at 5 weeks | Area under the ROC curve of ultrasound examination at 5 weeks compared with CT scan at 5 weeks for making the diagnosis of HO. | at 5 weeks | |
Secondary | Clinical examination | Area under the ROC curve of clinical examination at 1, 2, 3, 4, 5 weeks of admission compared with CT scan at 5 weeks to screen HO. | weekly from week-1 to week-5 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03724422 -
HO Prophylaxis Therapy for Distal Humerus Fractures
|
N/A | |
Withdrawn |
NCT00586365 -
Naproxen for the Prevention of HO After Complex Elbow Trauma
|
Phase 4 | |
Enrolling by invitation |
NCT04867278 -
Heterotopic Ossification Prophylaxis
|
N/A | |
Completed |
NCT03925688 -
Assessment of Heterotopic Ossification of Elbow Joint in Relation of Serum Uric Acid.
|
||
Withdrawn |
NCT00262392 -
Study of Pamidronate for the Prevention of Heterotopic Ossification
|
N/A | |
Withdrawn |
NCT04867018 -
Defining the Pathophysiology of Heterotopic Ossification: A Prospective Study
|
||
Completed |
NCT01539447 -
Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy
|
Early Phase 1 | |
Completed |
NCT05218954 -
Balance in Patients With Ectopic Bone Tissue After Total Hip Replacement
|
||
Completed |
NCT06251349 -
Comparative Analysis of Radiotherapeutic and Medical Procedures for the Prophylaxis of Heterotopic Ossifications
|
||
Completed |
NCT06088407 -
Tranexamic Acid Prophylaxis for Heterotopic Ossification in Elbow Fracture-Dislocation Surgery
|
N/A | |
Completed |
NCT03974698 -
Uncemented Hemiarthroplasty, Radiological Features Comparing Lateral Versus Anterolateral Approach
|
N/A | |
Enrolling by invitation |
NCT05648916 -
Celebrex and HO Study
|